Design of comprehensive Alzheimer's disease centers to address unmet national needs

John Q. Trojanowski, Steven E. Arnold, Jason H. Karlawish, Kurt Brunden, Mark Cary, Christos Davatzikos, John Detre, Glen Gaulton, Murray Grossman, Howard Hurtig, Kathryn Jedrziewski, Leo McCluskey, Mary Naylor, Daniel E. Polsky, Gerard D. Schellenberg, Andrew Siderowf, Leslie M. Shaw, Vivianna Van Deerlin, Li San Wang, Rachel Werner & 2 others Sharon X. Xie, Virginia M Y Lee

Research output: Contribution to journalArticle

Abstract

The problem of Alzheimer's disease (AD) exemplifies the challenges of dealing with a broad range of aging-related chronic disorders that require long-term, labor-intensive, and expensive care. As the baby boom generation ages and brain diseases become more prevalent, the need to confront the pending health care crisis is more urgent than ever before. Indeed, there is now a critical need to expand significantly the national effort to solve the problem of AD, with special focus on prevention. The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020) aims to create a new paradigm for planning and supporting the organization of worldwide cooperative research networks to develop new technologies for early detection and treatments of aging-related memory and motor impairments. PAD 2020 is developing an implementation plan to justify (1) increasing the federal budget for research, (2) developing novel national resources to discover new interventions for memory and motor disorders, and (3) creating innovative and streamlined decision-making processes for selecting and supporting new ideas. Since 1978 the National Institute on Aging or National Institute of Health (NIH) established an extensive national network of AD research facilities at academic institutions including AD Centers (ADCs), Consortium to Establish a Registry for AD, AD Cooperative Study (ADCS), AD Drug Discovery Program, National Alzheimer's Coordinating Center, National Cell Repository for AD, and AD Neuroimaging Initiative. However, despite the success of these programs and their critical contributions, they are no longer adequate to meet the challenges presented by AD. PAD 2020 is designed to address these changes by improving the efficiency and effectiveness of these programs. For example, the ADCs (P30s and P50s) can be enhanced by converting some into Comprehensive Alzheimer's Disease Centers (CADCs) to support not only research, but also by being demonstration projects on care/treatment, clinical trials, and education as well as by seamlessly integrating multisite collaborative studies (ADCS, AD Neuroimaging Initiative, Patient Registries, Clinical Data Banks, etc) into a cohesive structure that further enhances the original mission of the National Institute on Aging ADCs. Regional CADCs offer greater efficiency and cost savings while serving as coordinating hubs of existing ADCs, thereby offering greater economies of scale and programmatic integration. The CADCs also broaden the scope of ADC activities to include research on interventions, diagnosis, imaging, prevention trials, and other longitudinal studies that require long-term support. Thus, CADCs can address the urgent need to identify subjects at high risk of AD for prevention trials and very early in the course of AD for clinical trials of disease modification. The enhanced CADCs will allow more flexibility among ADCs by supporting collaborative linkages with other institutions and drawing on a wider expertise from different locations. This perspective article describes the University of Pennsylvania (Penn) CADC Model as an illustrative example of how an existing ADC can be converted into a CADC by better utilization of Penn academic resources to address the wide range of problems concerning AD. The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders.

Original languageEnglish (US)
Pages (from-to)150-155
Number of pages6
JournalAlzheimer's and Dementia
Volume6
Issue number2
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Alzheimer Disease
National Institute on Aging (U.S.)
Research
Neuroimaging
Registries
Organizational Efficiency
Clinical Trials
Cost Savings
Population Growth
Memory Disorders
Movement Disorders
National Institutes of Health (U.S.)
Program Evaluation
Brain Diseases
Budgets
Drug Discovery
Critical Care

Keywords

  • Alzheimer's disease
  • Basic science
  • Clinical trials
  • Drug discovery
  • Health care policy
  • Health services
  • Neurodegenerative diseases
  • Neuroimaging
  • Prevention

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Trojanowski, J. Q., Arnold, S. E., Karlawish, J. H., Brunden, K., Cary, M., Davatzikos, C., ... Lee, V. M. Y. (2010). Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimer's and Dementia, 6(2), 150-155. https://doi.org/10.1016/j.jalz.2009.11.004

Design of comprehensive Alzheimer's disease centers to address unmet national needs. / Trojanowski, John Q.; Arnold, Steven E.; Karlawish, Jason H.; Brunden, Kurt; Cary, Mark; Davatzikos, Christos; Detre, John; Gaulton, Glen; Grossman, Murray; Hurtig, Howard; Jedrziewski, Kathryn; McCluskey, Leo; Naylor, Mary; Polsky, Daniel E.; Schellenberg, Gerard D.; Siderowf, Andrew; Shaw, Leslie M.; Van Deerlin, Vivianna; Wang, Li San; Werner, Rachel; Xie, Sharon X.; Lee, Virginia M Y.

In: Alzheimer's and Dementia, Vol. 6, No. 2, 03.2010, p. 150-155.

Research output: Contribution to journalArticle

Trojanowski, JQ, Arnold, SE, Karlawish, JH, Brunden, K, Cary, M, Davatzikos, C, Detre, J, Gaulton, G, Grossman, M, Hurtig, H, Jedrziewski, K, McCluskey, L, Naylor, M, Polsky, DE, Schellenberg, GD, Siderowf, A, Shaw, LM, Van Deerlin, V, Wang, LS, Werner, R, Xie, SX & Lee, VMY 2010, 'Design of comprehensive Alzheimer's disease centers to address unmet national needs', Alzheimer's and Dementia, vol. 6, no. 2, pp. 150-155. https://doi.org/10.1016/j.jalz.2009.11.004
Trojanowski JQ, Arnold SE, Karlawish JH, Brunden K, Cary M, Davatzikos C et al. Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimer's and Dementia. 2010 Mar;6(2):150-155. https://doi.org/10.1016/j.jalz.2009.11.004
Trojanowski, John Q. ; Arnold, Steven E. ; Karlawish, Jason H. ; Brunden, Kurt ; Cary, Mark ; Davatzikos, Christos ; Detre, John ; Gaulton, Glen ; Grossman, Murray ; Hurtig, Howard ; Jedrziewski, Kathryn ; McCluskey, Leo ; Naylor, Mary ; Polsky, Daniel E. ; Schellenberg, Gerard D. ; Siderowf, Andrew ; Shaw, Leslie M. ; Van Deerlin, Vivianna ; Wang, Li San ; Werner, Rachel ; Xie, Sharon X. ; Lee, Virginia M Y. / Design of comprehensive Alzheimer's disease centers to address unmet national needs. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 2. pp. 150-155.
@article{704256242bf340148f2bcb0dd6be2a0f,
title = "Design of comprehensive Alzheimer's disease centers to address unmet national needs",
abstract = "The problem of Alzheimer's disease (AD) exemplifies the challenges of dealing with a broad range of aging-related chronic disorders that require long-term, labor-intensive, and expensive care. As the baby boom generation ages and brain diseases become more prevalent, the need to confront the pending health care crisis is more urgent than ever before. Indeed, there is now a critical need to expand significantly the national effort to solve the problem of AD, with special focus on prevention. The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020) aims to create a new paradigm for planning and supporting the organization of worldwide cooperative research networks to develop new technologies for early detection and treatments of aging-related memory and motor impairments. PAD 2020 is developing an implementation plan to justify (1) increasing the federal budget for research, (2) developing novel national resources to discover new interventions for memory and motor disorders, and (3) creating innovative and streamlined decision-making processes for selecting and supporting new ideas. Since 1978 the National Institute on Aging or National Institute of Health (NIH) established an extensive national network of AD research facilities at academic institutions including AD Centers (ADCs), Consortium to Establish a Registry for AD, AD Cooperative Study (ADCS), AD Drug Discovery Program, National Alzheimer's Coordinating Center, National Cell Repository for AD, and AD Neuroimaging Initiative. However, despite the success of these programs and their critical contributions, they are no longer adequate to meet the challenges presented by AD. PAD 2020 is designed to address these changes by improving the efficiency and effectiveness of these programs. For example, the ADCs (P30s and P50s) can be enhanced by converting some into Comprehensive Alzheimer's Disease Centers (CADCs) to support not only research, but also by being demonstration projects on care/treatment, clinical trials, and education as well as by seamlessly integrating multisite collaborative studies (ADCS, AD Neuroimaging Initiative, Patient Registries, Clinical Data Banks, etc) into a cohesive structure that further enhances the original mission of the National Institute on Aging ADCs. Regional CADCs offer greater efficiency and cost savings while serving as coordinating hubs of existing ADCs, thereby offering greater economies of scale and programmatic integration. The CADCs also broaden the scope of ADC activities to include research on interventions, diagnosis, imaging, prevention trials, and other longitudinal studies that require long-term support. Thus, CADCs can address the urgent need to identify subjects at high risk of AD for prevention trials and very early in the course of AD for clinical trials of disease modification. The enhanced CADCs will allow more flexibility among ADCs by supporting collaborative linkages with other institutions and drawing on a wider expertise from different locations. This perspective article describes the University of Pennsylvania (Penn) CADC Model as an illustrative example of how an existing ADC can be converted into a CADC by better utilization of Penn academic resources to address the wide range of problems concerning AD. The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders.",
keywords = "Alzheimer's disease, Basic science, Clinical trials, Drug discovery, Health care policy, Health services, Neurodegenerative diseases, Neuroimaging, Prevention",
author = "Trojanowski, {John Q.} and Arnold, {Steven E.} and Karlawish, {Jason H.} and Kurt Brunden and Mark Cary and Christos Davatzikos and John Detre and Glen Gaulton and Murray Grossman and Howard Hurtig and Kathryn Jedrziewski and Leo McCluskey and Mary Naylor and Polsky, {Daniel E.} and Schellenberg, {Gerard D.} and Andrew Siderowf and Shaw, {Leslie M.} and {Van Deerlin}, Vivianna and Wang, {Li San} and Rachel Werner and Xie, {Sharon X.} and Lee, {Virginia M Y}",
year = "2010",
month = "3",
doi = "10.1016/j.jalz.2009.11.004",
language = "English (US)",
volume = "6",
pages = "150--155",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Design of comprehensive Alzheimer's disease centers to address unmet national needs

AU - Trojanowski, John Q.

AU - Arnold, Steven E.

AU - Karlawish, Jason H.

AU - Brunden, Kurt

AU - Cary, Mark

AU - Davatzikos, Christos

AU - Detre, John

AU - Gaulton, Glen

AU - Grossman, Murray

AU - Hurtig, Howard

AU - Jedrziewski, Kathryn

AU - McCluskey, Leo

AU - Naylor, Mary

AU - Polsky, Daniel E.

AU - Schellenberg, Gerard D.

AU - Siderowf, Andrew

AU - Shaw, Leslie M.

AU - Van Deerlin, Vivianna

AU - Wang, Li San

AU - Werner, Rachel

AU - Xie, Sharon X.

AU - Lee, Virginia M Y

PY - 2010/3

Y1 - 2010/3

N2 - The problem of Alzheimer's disease (AD) exemplifies the challenges of dealing with a broad range of aging-related chronic disorders that require long-term, labor-intensive, and expensive care. As the baby boom generation ages and brain diseases become more prevalent, the need to confront the pending health care crisis is more urgent than ever before. Indeed, there is now a critical need to expand significantly the national effort to solve the problem of AD, with special focus on prevention. The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020) aims to create a new paradigm for planning and supporting the organization of worldwide cooperative research networks to develop new technologies for early detection and treatments of aging-related memory and motor impairments. PAD 2020 is developing an implementation plan to justify (1) increasing the federal budget for research, (2) developing novel national resources to discover new interventions for memory and motor disorders, and (3) creating innovative and streamlined decision-making processes for selecting and supporting new ideas. Since 1978 the National Institute on Aging or National Institute of Health (NIH) established an extensive national network of AD research facilities at academic institutions including AD Centers (ADCs), Consortium to Establish a Registry for AD, AD Cooperative Study (ADCS), AD Drug Discovery Program, National Alzheimer's Coordinating Center, National Cell Repository for AD, and AD Neuroimaging Initiative. However, despite the success of these programs and their critical contributions, they are no longer adequate to meet the challenges presented by AD. PAD 2020 is designed to address these changes by improving the efficiency and effectiveness of these programs. For example, the ADCs (P30s and P50s) can be enhanced by converting some into Comprehensive Alzheimer's Disease Centers (CADCs) to support not only research, but also by being demonstration projects on care/treatment, clinical trials, and education as well as by seamlessly integrating multisite collaborative studies (ADCS, AD Neuroimaging Initiative, Patient Registries, Clinical Data Banks, etc) into a cohesive structure that further enhances the original mission of the National Institute on Aging ADCs. Regional CADCs offer greater efficiency and cost savings while serving as coordinating hubs of existing ADCs, thereby offering greater economies of scale and programmatic integration. The CADCs also broaden the scope of ADC activities to include research on interventions, diagnosis, imaging, prevention trials, and other longitudinal studies that require long-term support. Thus, CADCs can address the urgent need to identify subjects at high risk of AD for prevention trials and very early in the course of AD for clinical trials of disease modification. The enhanced CADCs will allow more flexibility among ADCs by supporting collaborative linkages with other institutions and drawing on a wider expertise from different locations. This perspective article describes the University of Pennsylvania (Penn) CADC Model as an illustrative example of how an existing ADC can be converted into a CADC by better utilization of Penn academic resources to address the wide range of problems concerning AD. The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders.

AB - The problem of Alzheimer's disease (AD) exemplifies the challenges of dealing with a broad range of aging-related chronic disorders that require long-term, labor-intensive, and expensive care. As the baby boom generation ages and brain diseases become more prevalent, the need to confront the pending health care crisis is more urgent than ever before. Indeed, there is now a critical need to expand significantly the national effort to solve the problem of AD, with special focus on prevention. The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020) aims to create a new paradigm for planning and supporting the organization of worldwide cooperative research networks to develop new technologies for early detection and treatments of aging-related memory and motor impairments. PAD 2020 is developing an implementation plan to justify (1) increasing the federal budget for research, (2) developing novel national resources to discover new interventions for memory and motor disorders, and (3) creating innovative and streamlined decision-making processes for selecting and supporting new ideas. Since 1978 the National Institute on Aging or National Institute of Health (NIH) established an extensive national network of AD research facilities at academic institutions including AD Centers (ADCs), Consortium to Establish a Registry for AD, AD Cooperative Study (ADCS), AD Drug Discovery Program, National Alzheimer's Coordinating Center, National Cell Repository for AD, and AD Neuroimaging Initiative. However, despite the success of these programs and their critical contributions, they are no longer adequate to meet the challenges presented by AD. PAD 2020 is designed to address these changes by improving the efficiency and effectiveness of these programs. For example, the ADCs (P30s and P50s) can be enhanced by converting some into Comprehensive Alzheimer's Disease Centers (CADCs) to support not only research, but also by being demonstration projects on care/treatment, clinical trials, and education as well as by seamlessly integrating multisite collaborative studies (ADCS, AD Neuroimaging Initiative, Patient Registries, Clinical Data Banks, etc) into a cohesive structure that further enhances the original mission of the National Institute on Aging ADCs. Regional CADCs offer greater efficiency and cost savings while serving as coordinating hubs of existing ADCs, thereby offering greater economies of scale and programmatic integration. The CADCs also broaden the scope of ADC activities to include research on interventions, diagnosis, imaging, prevention trials, and other longitudinal studies that require long-term support. Thus, CADCs can address the urgent need to identify subjects at high risk of AD for prevention trials and very early in the course of AD for clinical trials of disease modification. The enhanced CADCs will allow more flexibility among ADCs by supporting collaborative linkages with other institutions and drawing on a wider expertise from different locations. This perspective article describes the University of Pennsylvania (Penn) CADC Model as an illustrative example of how an existing ADC can be converted into a CADC by better utilization of Penn academic resources to address the wide range of problems concerning AD. The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders.

KW - Alzheimer's disease

KW - Basic science

KW - Clinical trials

KW - Drug discovery

KW - Health care policy

KW - Health services

KW - Neurodegenerative diseases

KW - Neuroimaging

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=77949340811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949340811&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2009.11.004

DO - 10.1016/j.jalz.2009.11.004

M3 - Article

VL - 6

SP - 150

EP - 155

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -